Factors associated with response to clozapine in schizophrenia: A review

Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Haruo Kashima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Clozapine has been serving as the gold standard medication for patients with treatment-resistant schizophrenia who failed to respond to other antipsychotics. However, factors affecting response to this medication have not been comprehensively reviewed recently. Methods: In order to find factors associated with response to clozapine in schizophrenia, a literature search was conducted using PubMed through January 2011 with keywords of clozapine, response, and schizophrenia. Cross-referencing of relevant articles was also performed. Factors were arbitrarily classified into the following: demographic/clinical, oral dosage/pharmacokinetic, biochemical, (electro)physiological, genetic, imaging, and combinations. Results: A synthesis from 280 articles indicated that demographic and clinical variables such as high baseline symptoms and low premorbid functioning have not been particularly useful in predicting response to clozapine. Pharmacokinetic evidence points to a threshold clozapine level of 350 ng/ml but in a context of significant inter- as well as intra-individual variability. Pharmacokinetic perspectives appear to have more implication in special situations including poor response, suspected toxicity and nonadherence. A number of laboratory-based studies have reported on many potential candidates for response prediction to clozapine, however, reproducibility, specificity, robustness of the findings, as well as clinical feasibility and cost-effectiveness all pose a significant practical challenge, in relation with the fact that pathophysiological bases of treatment resistance in schizophrenia largely remain to be elucidated. Conclusions: No unequivocal factors to clozapine response were found despite a relatively rich body of the literature, which calls for more works on this important topic. Clozapine level of 350 ng/ml appears to be useful in case of nonresponse.

Original languageEnglish
Pages (from-to)32-60
Number of pages29
JournalPsychopharmacology Bulletin
Volume44
Issue number1
Publication statusPublished - 2011

Fingerprint

Clozapine
Schizophrenia
Pharmacokinetics
Demography
PubMed
Antipsychotic Agents
Cost-Benefit Analysis
Therapeutics

Keywords

  • Clozapine
  • Factor
  • Predictor
  • Response
  • Review
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Factors associated with response to clozapine in schizophrenia : A review. / Suzuki, Takefumi; Uchida, Hiroyuki; Watanabe, Koichiro; Kashima, Haruo.

In: Psychopharmacology Bulletin, Vol. 44, No. 1, 2011, p. 32-60.

Research output: Contribution to journalArticle

Suzuki, T, Uchida, H, Watanabe, K & Kashima, H 2011, 'Factors associated with response to clozapine in schizophrenia: A review', Psychopharmacology Bulletin, vol. 44, no. 1, pp. 32-60.
Suzuki, Takefumi ; Uchida, Hiroyuki ; Watanabe, Koichiro ; Kashima, Haruo. / Factors associated with response to clozapine in schizophrenia : A review. In: Psychopharmacology Bulletin. 2011 ; Vol. 44, No. 1. pp. 32-60.
@article{be2d0020e9694e6087e46ba261da1fce,
title = "Factors associated with response to clozapine in schizophrenia: A review",
abstract = "Background: Clozapine has been serving as the gold standard medication for patients with treatment-resistant schizophrenia who failed to respond to other antipsychotics. However, factors affecting response to this medication have not been comprehensively reviewed recently. Methods: In order to find factors associated with response to clozapine in schizophrenia, a literature search was conducted using PubMed through January 2011 with keywords of clozapine, response, and schizophrenia. Cross-referencing of relevant articles was also performed. Factors were arbitrarily classified into the following: demographic/clinical, oral dosage/pharmacokinetic, biochemical, (electro)physiological, genetic, imaging, and combinations. Results: A synthesis from 280 articles indicated that demographic and clinical variables such as high baseline symptoms and low premorbid functioning have not been particularly useful in predicting response to clozapine. Pharmacokinetic evidence points to a threshold clozapine level of 350 ng/ml but in a context of significant inter- as well as intra-individual variability. Pharmacokinetic perspectives appear to have more implication in special situations including poor response, suspected toxicity and nonadherence. A number of laboratory-based studies have reported on many potential candidates for response prediction to clozapine, however, reproducibility, specificity, robustness of the findings, as well as clinical feasibility and cost-effectiveness all pose a significant practical challenge, in relation with the fact that pathophysiological bases of treatment resistance in schizophrenia largely remain to be elucidated. Conclusions: No unequivocal factors to clozapine response were found despite a relatively rich body of the literature, which calls for more works on this important topic. Clozapine level of 350 ng/ml appears to be useful in case of nonresponse.",
keywords = "Clozapine, Factor, Predictor, Response, Review, Schizophrenia",
author = "Takefumi Suzuki and Hiroyuki Uchida and Koichiro Watanabe and Haruo Kashima",
year = "2011",
language = "English",
volume = "44",
pages = "32--60",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Factors associated with response to clozapine in schizophrenia

T2 - A review

AU - Suzuki, Takefumi

AU - Uchida, Hiroyuki

AU - Watanabe, Koichiro

AU - Kashima, Haruo

PY - 2011

Y1 - 2011

N2 - Background: Clozapine has been serving as the gold standard medication for patients with treatment-resistant schizophrenia who failed to respond to other antipsychotics. However, factors affecting response to this medication have not been comprehensively reviewed recently. Methods: In order to find factors associated with response to clozapine in schizophrenia, a literature search was conducted using PubMed through January 2011 with keywords of clozapine, response, and schizophrenia. Cross-referencing of relevant articles was also performed. Factors were arbitrarily classified into the following: demographic/clinical, oral dosage/pharmacokinetic, biochemical, (electro)physiological, genetic, imaging, and combinations. Results: A synthesis from 280 articles indicated that demographic and clinical variables such as high baseline symptoms and low premorbid functioning have not been particularly useful in predicting response to clozapine. Pharmacokinetic evidence points to a threshold clozapine level of 350 ng/ml but in a context of significant inter- as well as intra-individual variability. Pharmacokinetic perspectives appear to have more implication in special situations including poor response, suspected toxicity and nonadherence. A number of laboratory-based studies have reported on many potential candidates for response prediction to clozapine, however, reproducibility, specificity, robustness of the findings, as well as clinical feasibility and cost-effectiveness all pose a significant practical challenge, in relation with the fact that pathophysiological bases of treatment resistance in schizophrenia largely remain to be elucidated. Conclusions: No unequivocal factors to clozapine response were found despite a relatively rich body of the literature, which calls for more works on this important topic. Clozapine level of 350 ng/ml appears to be useful in case of nonresponse.

AB - Background: Clozapine has been serving as the gold standard medication for patients with treatment-resistant schizophrenia who failed to respond to other antipsychotics. However, factors affecting response to this medication have not been comprehensively reviewed recently. Methods: In order to find factors associated with response to clozapine in schizophrenia, a literature search was conducted using PubMed through January 2011 with keywords of clozapine, response, and schizophrenia. Cross-referencing of relevant articles was also performed. Factors were arbitrarily classified into the following: demographic/clinical, oral dosage/pharmacokinetic, biochemical, (electro)physiological, genetic, imaging, and combinations. Results: A synthesis from 280 articles indicated that demographic and clinical variables such as high baseline symptoms and low premorbid functioning have not been particularly useful in predicting response to clozapine. Pharmacokinetic evidence points to a threshold clozapine level of 350 ng/ml but in a context of significant inter- as well as intra-individual variability. Pharmacokinetic perspectives appear to have more implication in special situations including poor response, suspected toxicity and nonadherence. A number of laboratory-based studies have reported on many potential candidates for response prediction to clozapine, however, reproducibility, specificity, robustness of the findings, as well as clinical feasibility and cost-effectiveness all pose a significant practical challenge, in relation with the fact that pathophysiological bases of treatment resistance in schizophrenia largely remain to be elucidated. Conclusions: No unequivocal factors to clozapine response were found despite a relatively rich body of the literature, which calls for more works on this important topic. Clozapine level of 350 ng/ml appears to be useful in case of nonresponse.

KW - Clozapine

KW - Factor

KW - Predictor

KW - Response

KW - Review

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=82155201483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155201483&partnerID=8YFLogxK

M3 - Article

C2 - 22506438

AN - SCOPUS:82155201483

VL - 44

SP - 32

EP - 60

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -